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Introduction
Flightless I (Flii) is a multifunctional protein of the gelsolin fam-
ily of actin-remodelling proteins. There are eight members of this 
family in mouse and humans, each containing one or two gelsolin 
domains consisting of three repeated gelsolin motifs of between 
125 and 150 amino acids in length.1 Flii contains 6 repeat gelsolin 
motifs and an additional 11 Leucine Rich Repeat (LRR) domains 
not present in other family members.2,3 It has been found to play 
roles in many processes including actin regulation, transcription 
and inflammation. Flii is distributed across many cellular com-
partments, as would be expected for such a multifunctional pro-
tein, including the nucleus, cytosol and lysosomes.3 In vivo, Flii 
negatively regulates excisional wound, blister wound and burn 
injury repair.4-6 Flii overexpressing mice (FliiTg/Tg) have impaired 
healing with larger, less contracted wounds, reduced cell prolif-
eration and delayed epithelial migration. In contrast, mice with 
reduced levels of Flii (Flii+/-) have improved wound healing with 
increased epithelial migration and enhanced wound contraction.5 
Wounds in Flii overexpressing mice also show significantly ele-
vated levels of collagen I and overexpression of collagen is a major 
contributing factor to hypertrophic, or excessive scar formation.5 
Given Flii’s known role in processes that are all involved in regu-
lating tissue repair it is not surprising that it could alter the course 
of wound healing and scar formation.
Regulation of Actin and Transcription
Unlike many gelsolin family members, which enhance actin 
polymerisation and cap actin filaments, Flii binds actin fila-
ments and actin monomers and inhibits actin polymerisation.7,8 
Intracellular Flightless I (Flii), a gelsolin family member, has been found to have roles modulating actin regulation, 
transcriptional regulation and inflammation. In vivo Flii can regulate wound healing responses. We have recently shown 
that a pool of Flii is secreted by fibroblasts and macrophages, cells typically found in wounds, and its secretion can be 
upregulated upon wounding. We show that secreted Flii can bind to the bacterial cell wall component lipopolysaccharide 
and has the potential to regulate inflammation. We now show that secreted Flii is present in both acute and chronic 
wound fluid.
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Flii caps but does not sever actin filaments and thereby retards 
actin filament turnover.7,8 Flii associates with focal adhesions, 
which are specialized structures that link the actin cytoskel-
eton to the surface integrin receptors and anchor cells to the 
extracellular matrix, and can alter their formation.7,9 Cells with 
reduced levels of gelsolin migrate slower, while a reduction in 
Flii levels leads to an increase in migration.5 Both fibroblasts 
and keratinocytes, cells typically found in wounds, that have 
less Flii migrate faster in vitro and in vivo and vice versa.7,10 
The impaired wound healing seen in mice overexpressing Flii 
could in part be due to the ability of Flii to inhibit cell adhe-
sion and migration. However, Flii has several other functions, 
which could also contribute to its negative role in tissue repair. 
Like gelsolin, Flii has the ability to regulate transcription.11 Flii 
binds to hormone-activated nuclear receptors, including the 
estrogen and thyroid hormone receptor, as well as the coactiva-
tors GRIP1and CARM1.12 Flii positively regulates hormone-
stimulated gene expression by the estrogen receptor through its 
gelsolin region and is involved in the recruitment of the chro-
matin remodelling complex SW1/SNF to estrogen-responsive 
promoters.12,13 Flii also inhibits β-catenin and LEF1/TCF-
mediated transcription.14 Thus, Flii has the ability to alter tran-
scription in part through its gelsolin domains. Our new data 
has shown that in fibroblasts Flii is found in the nucleus of some 
but not all cells (Figs. 1 and 2)3 and it is probably this pool of 
Flii which may well be responsible for regulating transcription 
in these cells.15 Our new data further suggests that Flii may have 
distinct roles in different cell types or under specific conditions. 
We show that unlike fibroblasts, macrophages have little to no 
Flii in the nucleus whether they were activated or not suggesting 
that its roles could differ depending on cell type or stimulus.3
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impaired cellularization and gastrulation of the embryo indicat-
ing that Flii is essential developmental regulator and has addi-
tional important functions, which could be related to the role of 
the LRR domains.22
We have recently shown a pool of Flii is located in the cytosol 
and this pool may in part be responsible for its role in dampen-
ing inflammation.3,16,19 Although inflammation appears to be a 
necessary part of the normal adult wound healing process, exces-
sive activation of TLR receptors and the subsequent increased or 
prolonged inflammatory response can induce considerable tissue 
damage which can lead to impaired healing. Flii is upregulated 
in mouse wounds peaking around day 7 when the inflammatory 
stage of tissue repair is being switched off.5 Whether Flii is play-
ing a role in dampening inflammation during tissue repair has 
yet to be tested in vivo. However in vitro Flii has been shown 
to dampen inflammation in multiple ways. In macrophages Flii 
is located in a complex with the TLR adaptor protein MyD88 
through its interaction with nucleoredoxin.17,19 Binding of Flii to 
this complex inhibits MyD88 binding to TLR4, which results 
in the inhibition TLR signaling pathways and reduces cytokine 
secretion.17,19 We recently found a pool of Flii localized to late 
endosomes/lysosomes in fibroblasts and macrophages where it 
may also have a role in dampening inflammation.3,18 Flii binds 
Flii’s Role in Regulating Inflammation
In recent years it has becoming increasingly obvious that Flii 
has an important role in dampening inflammation.3,16-19 Unlike 
other gelsolin family members Flii has 11 LRR domains in the 
N-terminus.3 These LRR domains share nearly 50% similarity to 
the LRR domains of the immune related receptor toll-like recep-
tor (TLR) 4. The immune system detects infection or injury via 
the LRR domains of TLRs.20 They can bind to pathogen-asso-
ciated molecular pattern (PAMPs) molecules, such as the gram-
negative bacteria cell wall component lipopolysaccharide or to 
damage-associated molecular pattern (DAMPs) molecules such 
as HMGB1 that are released from damaged and dying cells, as 
well as extracellular matrix cleavage products.21 Their binding 
in turn activates intracellular TLR signaling pathways that ulti-
mately lead to the secretion of cytokines. Typically both DAMPs 
and PAMPs are present in wounds. The importance of these 
domains in Flii was first hinted at by mouse knockout studies of 
Flii and other gelsolin family members.15 Apart from Flii, mice 
lacking members of the gelsolin family are viable, but with actin 
defects.15 In contrast, homozygous disruption of the Flii gene in 
mice leads to very early failure of embryonic development with 
Figure 1. Flii is not found in the classical secretory pathway in fibroblasts. Primary fibroblasts were fixed with methanol, immunostained for Flii (mouse 
anti-Flii antibody) in combination with the recycling endosome SNARE protein VAMP3 (A) or the trans-Golgi complex and recycling endosome SNARE 
Vti1b (B). Flii is not located in compartments of the classical secretory pathway in fibroblasts.
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to ligands, thus limiting the stimulation of TLR signaling and 
inflammation. It is possible given the timing of Flii’s upregula-
tion after injury that Flii could be potentially playing a role in 
limiting the inflammatory response both from within the cells 
to caspase-1 and in doing so inhibits the maturation of the 
cytokine pro-interleukin-1β to pro-interleukin-1β in macro-
phages, thus reducing its secretion.18 Exactly where in the cell 
pro-interleukin-1β is cleaved to form the mature secreted form is 
controversial; however, there is data to suggest it may take place 
in the lysosome and that the mature form can be secreted from 
this compartment.23
Flii is Secreted and the Secreted Form  
also has the Potential to Alter Inflammation
Flii was thought to be solely an intracellular protein, however, our 
recent study has shown that in vitro Flii is constitutively secreted 
by at least two cell types typically found in wounds; macrophages 
and fibroblasts.3 This secretion from fibroblasts can be upregu-
lated in response to wounding and by macrophages in response to 
LPS stimulation.3 The upregulation in secretion after wounding 
suggest this pool of Flii may play a role during the repair process. 
In macrophages Flii localizes to late endosomes/lysosomes but not 
to compartments typically associated with the classical secretory 
pathway, for example the Golgi complex in macrophages.3 Similar 
results are shown here for primary fibroblasts (Figs.  1 and 2). 
Flii does not colocate with the trans-Golgi network and recycling 
endosome-associated SNARE protein Vti1b in primary fibroblasts 
(Fig. 1A) or with the recycling endosome associated SNARE pro-
tein VAMP3 (Fig. 1B). However, a pool of Flii colocalizes with 
the lysosomal enzyme Cathepsin D in these cells (Fig. 2A). Our 
recent data shows that Flii is secreted from macrophages via late 
endosomes/lysosomes in a manner regulated by Rab7 and Stx11.3 
This data suggests that Flii may therefore not only affect cellu-
lar activities via its intracellular/nuclear functions but it may also 
have important extracellular activities.
In vivo, we have shown that Flii is also present in human 
plasma samples.3 Given Flii’s important role in wound healing we 
have now looked to see whether Flii is secreted into wound fluid 
from a number of sources. We find that secreted Flii is also pres-
ent in acute wound fluid from patients undergoing abdomino-
plasty and in blister fluid as well as in chronic wound fluid taken 
from patients with venous leg ulcers (Fig. 3A). Exactly what role 
Flii is playing in the wound fluid is currently unclear; however 
our results suggest that Flii can form a complex with the bacterial 
cell wall protein lipopolysaccharide (LPS).3 An antibody to the 
first LLR domain is able to inhibit formation of this complex sug-
gesting that the LRR region might be involved in this process.3 
Altering the level of secreted Flii in the media showed that Flii 
can negatively influence the LPS induced production and secre-
tion of cytokine, such that cells stimulated with LPS in the pres-
ence of media with higher levels of Flii have reduced production 
and secretion of TNF.3 Thus, it would appear that secreted Flii 
has the potential to dampen inflammation.
Prolonged or augmented inflammation can induce significant 
tissue damage unfavorable to the repair process thus the body has 
developed mechanisms that finely tune and regulate TLR acti-
vation. For example, surface TLR expression is downregulated 
after activation and at the same time soluble TLRs are secreted 
that compete with their membrane-associated forms for binding 
Figure 2. Flii is located in late endosomes/lysosomes in fibroblasts. (A) 
Primary fibroblasts were fixed with methanol, immunostained for Flii 
(mouse anti-Flii antibody) and the late endosomal/lysosomal enzyme 
cathepsin D (CatD). Flii co-localizes with cathepsin D in late endosomes/
lysosomes in fibroblasts.
Figure 3. Flii is present in wound fluid from acute and chronic wounds. 
The clinical investigations were conducted under approval from the 
Women’s and Children’s Health Network Human Research Ethics Com-
mittee, Adelaide, Australia, in accordance to the Declaration of Helsinski 
principles and with written informed consent. (A) Wound fluid col-
lected from patients undergoing abdominoplasty, from blister fluid and 
from patients with venous leg ulcers was immunoblotted for Flii and 
albumin. Flii is secreted into both acute and chronic wounds.
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